Oxford starts childhood vaccination trials in step towards pedigree pandemic

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

The University of Oxford will begin testing the Covid-19 vaccine with which it was developed AstraZeneca Plc on children, a potentially important step in ending the global pandemic.

The Oxford trial plans to enroll 300 children deprecated 6 to 17, the university said in a statement Saturday. The first vaccinations will take place this month, with as many as 240 children receiving the coronavirus vaccine and the rest a meningitis shot, which should cause similar side effects. Later in the US, Astra is expected to conduct a larger trial involving thousands of children.

The phase II study will take place in Oxford and three UK cities – London, Southampton and Bristol – and will assess safety and immune responses in children. Researchers will test the shot on children deprecated 12 to 17 years before moving into the younger age group, with initial data expected by summer, Andrew Pollard, lead investigator on the trial, said in a Bloomberg interview.

The study will look at two dosing regimens one month and three months apart, Pollard said.

Source